Printer Friendly

BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON FINDINGS OF CLINICAL BENEFITS OF VIDEX

 BRISTOL-MYERS SQUIBB ISSUES STATEMENT
 ON FINDINGS OF CLINICAL BENEFITS OF VIDEX
 NEW YORK, April 20 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) issued the following statement:
 We are encouraged that the FDA Antiviral Drugs Advisory Committee is in agreement that the clinical benefits of VIDEX have been confirmed.
 Bristol-Myers Squibb has not yet formally approached FDA regarding expanded labelling of VIDEX, nor did the committee vote on expanded labelling today, but we anticipate an appropriate discussion with FDA on this topic in the near future. Stephen K. Carter, M.D., senior vice president, Worldwide Clinical Research and Development, said, "We will negotiate with FDA on how the VIDEX label could be expanded to encourage the most appropriate use of the drug."
 We are committed to continued studies of VIDEX to provide the most up-to-date and accurate assessment of the use of this important compound in the management of the HIV disease.
 -0- 4/20/92
 /CONTACT: Susan J. Yarin, 212-546-5709, or Elizabeth M. Sigler, 212-546-5764, both of Bristol-Myers Squibb; or Brian Hujdich or Lisa Dowdell for VIDEX Media Information Service, 202-638-4339/
 (BMY) CO: VIDEX Media Information Service; Bristol-Myers Squibb ST: New York IN: HEA MTC SU:


MH-DC -- DC010 -- 0188 04/20/92 15:39 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1992
Words:203
Previous Article:NASH FINCH REPORTS FIRST-QUARTER RESULTS
Next Article:WESTGROUP ACQUIRES GERMAN COMPANIES


Related Articles
BRISTOL-MYERS SQUIBB SUBMITS NEW DRUG APPLICATION TO FOOD AND DRUG ADMINISTRATION
BRISTOL-MYERS SQUIBB'S VIDEX APPROVED BY FDA FOR BROADER USE
RESULTS OF COMMUNITY BASED CLINICAL TRIAL OF AIDS DRUGS ANNOUNCED
BRISTOL-MYERS SQUIBB SUBMITS A SUPPLEMENTAL NEW DRUG APPLICATION FOR ZERIT(TM)
BRISTOL-MYERS SQUIBB STATEMENT REGARDING ACTG 175 STUDY COMPARING AZT TO OTHER ANTIRETROVIRALS
AIDS TRIALS SHOW CLINICAL BENEFIT OF VIDEX(R) IN COMBINATION THERAPY
VIDEX(R) PROLONGS LIVES AND DRAMATICALLY DELAYS PROGRESSION OF AIDS
FDA COMMITTEE UNANIMOUSLY RECOMMENDS APPROVAL OF VIDEX(R) AS FIRST-LINE TREATMENT FOR AIDS VIRUS
Zerit(R) (stavudine) Approved For First-Line Treatment of HIV in Europe; Indication Includes Adults and Children
d4T plus ddl: Warning for Pregnant Women.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters